Sage Products v. Purewick: Voluntary Dismissal in Medical Device Urinary Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Sage Products, LLC v. Purewick Corporation |
| Case Number | 24-1184 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from D.C. |
| Duration | Nov 2023 – Mar 2024 100 days |
| Outcome | Voluntary Dismissal — Each Party Bears Costs |
| Patents at Issue | |
| Accused Products | Purewick’s PrimaFit™ product |
Case Overview
The Parties
⚖️ Plaintiff
Recognized player in the healthcare disposables and patient care solutions market, holding a notable IP portfolio targeting hospital and clinical care products.
🛡️ Defendant
Markets the PrimaFit™ product line within the urinary management and incontinence care segment, a competitive and IP-dense market.
Patents at Issue
This case centered on four U.S. patents covering technology within the urinary management device space, including external urinary collection systems — a technically specific and commercially significant category within patient care product development.
- • US10226376B2 — Urinary management device
- • US8287508B1 — External urinary collection system
- • US10390989B2 — Suction-based urinary catheter
- • US10376407B2 — Continence management apparatus
Developing a similar medical device?
Check if your product design might infringe these or related patents before launch.
Litigation Timeline & Legal Analysis
Litigation Timeline & Procedural History
| Date Filed | November 22, 2023 |
| Court | U.S. Court of Appeals for the Federal Circuit |
| Date Closed | March 1, 2024 |
| Duration | 100 days |
| Basis of Termination | Voluntary Dismissal (Fed. R. App. P. 42(b)) |
This appeal was filed in the District of Columbia circuit region, reaching the Federal Circuit — the exclusive appellate jurisdiction for U.S. patent cases. The 100-day duration from filing to dismissal is notably brief for Federal Circuit proceedings, which typically involve extensive briefing schedules. The rapid resolution strongly suggests settlement negotiations were underway.
Outcome
The Federal Circuit ordered the proceeding dismissed under Federal Rule of Appellate Procedure 42(b), based on the parties’ mutual agreement. The court further ordered that each side shall bear its own costs. No damages were awarded, and no injunctive relief was granted or denied on the merits. The case closed without any substantive ruling on the validity or infringement of the four asserted patents.
Legal Significance
The voluntary dismissal means no binding precedent was created by this Federal Circuit proceeding. For the broader patent litigation community, this is significant: the four patents-in-suit retain their presumption of validity under 35 U.S.C. § 282, and no appellate claim construction ruling constrains their future assertion or licensing. Rule 42(b) dismissals at the Federal Circuit are relatively uncommon at the appellate stage and typically reflect a negotiated resolution or a strategic decision that appellate risk outweighs the benefit of continued litigation.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in medical device design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in medical device urinary management
- See which companies are most active in this technology space
- Understand patent claim trends and design-around opportunities
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical device.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
External urinary collection device technology
4 Patents at Issue
Focused on urinary management
Design-Around Options
Potential for strategic product modifications
✅ Key Takeaways
Voluntary Federal Circuit dismissal under Rule 42(b) preserves patent validity and leaves claim scope unconstrued — a strategically important outcome for plaintiffs managing portfolio risk.
Search related case law →Elite bilateral representation signals high-value underlying stakes despite the non-merits resolution.
Explore firm litigation histories →Four patents across multiple application families suggest a coordinated patent prosecution strategy worth studying for portfolio structuring.
Analyze patent family strategies →Frequently Asked Questions
Four U.S. patents: US10226376B2, US8287508B1, US10390989B2, and US10376407B2 — covering urinary management device technology.
The dismissal was voluntary under Fed. R. App. P. 42(b) by mutual agreement of both parties, with each side bearing its own costs. No merits ruling was issued.
The four asserted patents remain valid and uninterpreted by appellate claim construction, preserving Sage Products’ future assertion options while leaving Purewick without a binding invalidity or non-infringement ruling in its favor.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- U.S. Court of Appeals for the D.C. Circuit (Underlying district court region)
- United States Court of Appeals for the Federal Circuit — Case 24-1184
- U.S. Patent and Trademark Office — Patent Center
- Cornell Legal Information Institute — Fed. R. App. P. 42(b)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.